Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

61. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. 28438841 2017 04 25 2017 05 15 2017 05 15 1526-632X 88 17 2017 Apr 25 Neurology Neurology Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination (...) , and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. 1674-1680 10.1212/WNL.0000000000003685 To determine the incidence rates of sudden unexpected death in epilepsy (SUDEP) in different epilepsy populations and address the question of whether risk factors for SUDEP have been identified. Systematic review of evidence; modified Grading Recommendations Assessment, Development, and Evaluation process for developing conclusions; recommendations developed by consensus

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro

62. Topiramate monotherapy for juvenile myoclonic epilepsy.

Topiramate monotherapy for juvenile myoclonic epilepsy. BACKGROUND: Topiramate is a newer broad-spectrum antiepileptic drug (AED). Some studies have shown the benefits of topiramate monotherapy in the treatment of juvenile myoclonic epilepsy (JME). However, there are no current systematic reviews to determine the efficacy and tolerability of topiramate monotherapy in people with JME. This is an updated version of the original Cochrane Review published in Issue 12, 2015. OBJECTIVES: To evaluate (...) the efficacy and tolerability of topiramate monotherapy in the treatment of JME. SEARCH METHODS: For the latest update, on 21 February 2017 we searched Cochrane Epilepsy's Specialized Register, CENTRAL, MEDLINE, and ClinicalTrials.gov. We also searched ongoing trials registers, reference lists and relevant conference proceedings, and contacted study authors and pharmaceutical companies. SELECTION CRITERIA: We included randomized controlled trials (RCTs) investigating topiramate monotherapy versus placebo

Cochrane2017

63. Lacosamide (Vimpat) - partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.

Lacosamide (Vimpat) - partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy. Published 13 March 2017 Statement of Advice: lacosamide (Vimpat) 50mg / 100mg / 150mg / 200mg film-coated tablets / 10mg/mL solution for infusion / 10mg/mL syrup (No: 1231/17) UCB Pharma Limited 10 February 2017 ADVICE: in the absence of a submission from the holder of the marketing authorisation lacosamide (Vimpat) is not recommended for use within (...) NHS Scotland. Indication under review: As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice

Scottish Medicines Consortium2017

64. Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder

Pregabalin Zentiva k.s. - neuropathic pain, epilepsy, generalised anxiety disorder 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/14344/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment (...) of neuropathic pain, epilepsy and generalised anxiety disorder (GAD) The legal basis for this application refers to: Generic application (Article 10(1) of Directive No 2001/83/EC). The application submitted is composed of administrative information, complete quality data and a bioequivalence study with the reference medicinal product Lyrica instead of non-clinical and clinical unless justified otherwise. Information on paediatric requirements Not applicable Information relating to orphan market exclusivity

European Medicines Agency - EPARs2017

65. Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy.

Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. BACKGROUND: Poor adherence to antiepileptic medication is associated with increased mortality, morbidity and healthcare costs. In this review, we focus on interventions designed and tested in randomised controlled trials and quasi-randomised controlled trials to assist people with adherence to antiepileptic medication. This is an updated version of the original Cochrane review published in the Cochrane (...) Library, Issue 1, 2010. OBJECTIVES: To determine the effectiveness of interventions aimed at improving adherence to antiepileptic medication in adults and children with epilepsy. SEARCH METHODS: For the latest update, on 4 February 2016 we searched the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid 1946 to 4 February 2016), CINAHL Plus (EBSCOhost 1937 to 4 February 2016

Cochrane2017

66. Cardiac arrhythmias in focal epilepsy: a prospective long-term study.

Cardiac arrhythmias in focal epilepsy: a prospective long-term study. BACKGROUND: Patients with epilepsy are at risk of sudden unexpected death. Neurogenic cardiac arrhythmias have been postulated as a cause. Electrocardiograms (ECG) can be monitored by use of an implantable loop recorder for up to 18 months. We aimed to determine the frequency of cardiac arrhythmias in patients with refractory focal seizures over an extended period. METHODS: 20 patients received an implantable loop recorder (...) abnormalities are closely similar to those at greatest risk of sudden unexpected death in epilepsy. Asystole might underlie many of these deaths, which would have important implications for the investigation of similar patients and affect present cardiac-pacing policies.

Lancet2017

67. Use of fMRI in the presurgical evaluation of patients with epilepsy

Use of fMRI in the presurgical evaluation of patients with epilepsy Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share January 24, 2017 ; 88 (4) Special Article Practice guideline summary: Use of fMRI in the presurgical evaluation of patients with epilepsy Report (...) Health & Science University, Portland; Department of Neurology (J.A.F.), New York University, New York; and Clinical Epilepsy Section (W.H.T.), National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD. David Gloss From the Department of Neurology (J.P.S.), University of Alabama at Birmingham; Department of Neurology (D.G.), Charleston Area Medical Center, WV; Department of Neurology (J.R.B., S.J.S.), Medical College of Wisconsin, Milwaukee; Children's National Medical Center (W.D.G

American Academy of Neurology2017

68. Cannabidiol (Epidioloex) - To treat rare, severe forms of epilepsy

Cannabidiol (Epidioloex) - To treat rare, severe forms of epilepsy Drug Approval Package: Epidiolex (Cannabidiol) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Epidiolex (Cannabidiol) Company: GW Research Ltd. Application Number: 210365 Orig 1 Approval Date: 07/27/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

FDA - Drug Approval Package2017

77. Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients

Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Intravenous immunoglobulin (...) for treatment of intractable epilepsy in pediatric patients. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Health Problem: Intractable epilepsy is diagnosed in 5% to 20% of pediatric patients with new-onset epilepsy. If uncontrolled, seizures in childhood may have a detrimental or even catastrophic impact on the developing brain. A connection has been made between inflammatory processes and neurological disease, including epilepsy, which may present new therapeutic

Health Technology Assessment (HTA) Database.2017

78. Cannabinoids for refractory epilepsy treatment

Cannabinoids for refractory epilepsy treatment Cannabinoids for refractory epilepsy treatment Cannabinoids for refractory epilepsy treatment Soto N, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soto N, Pichon-Riviere A, Augustovski F (...) , García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Cannabinoids for refractory epilepsy treatment. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 499. 2016 Authors' conclusions There is scarce and low quality evidence on cannabinoids (specifically cannabidiol) potential in reducing the frequency of seizures in patients with refractory epilepsy. The Clinical Practice Guidelines and health sponsors consulted do

Health Technology Assessment (HTA) Database.2016

79. Relationship between Bone Density and Biochemical Markers of Bone among Two Groups Taking Carbamazepine and Sodium Valproate for Epilepsy in Comparison with Healthy Individuals in Yazd

Relationship between Bone Density and Biochemical Markers of Bone among Two Groups Taking Carbamazepine and Sodium Valproate for Epilepsy in Comparison with Healthy Individuals in Yazd 28070260 2018 11 13 2008-5842 8 11 2016 Nov Electronic physician Electron Physician Relationship between Bone Density and Biochemical Markers of Bone among Two Groups Taking Carbamazepine and Sodium Valproate for Epilepsy in Comparison with Healthy Individuals in Yazd. 3257-3265 10.19082/3257 Chronic (...) antiepileptic therapy has been associated with metabolic bone diseases including osteomalacia and osteoporosis. The aim of this study was to determine frequency of changes in biochemical and bone mineral density (BMD) in adults receiving valproaic acid (VPA) & carbamazepine (CBZ). In a cross sectional study evaluating adults (age 20-50 y) epileptic patients receiving valproic acid or carbamazepine for at least 2 years. This study was conducted from May 2014 to May 2015 in Shahid Sadoughi Hospital of Yazd

Electronic physician2016 Full Text: Link to full Text with Trip Pro

80. WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy.

WITHDRAWN: Oxcarbazepine add-on for drug-resistant partial epilepsy. BACKGROUND: Most people with epilepsy have a good prognosis and their seizures can be well controlled with the use of a single antiepileptic drug, but up to 30% develop refractory epilepsy, especially those with partial seizures. In this review we summarize the current evidence regarding oxcarbazepine when used as an add-on treatment for drug-resistant partial epilepsy. OBJECTIVES: To evaluate the effects of oxcarbazepine when (...) used as an add-on treatment for drug-resistant partial epilepsy. SEARCH METHODS: We searched the Cochrane Epilepsy Group's Specialized Register (28 March 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (1966 to March 2006). No language restrictions were imposed. We checked the reference lists of retrieved studies for additional reports of relevant studies. We also contacted Novartis (manufacturers of oxcarbazepine) and experts

Cochrane2016